Vimarsana
Biggest News Aggregation in the World

Mobile Nokia News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mobile Nokia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mobile Nokia Today - Breaking & Trending Today

Patients with asthma have more favorable COVID-19 outcomes in inner-city population - Vimarsana News

Patients with asthma have more favorable COVID-19 outcomes in inner-city population

SAN ANTONIO — Patients with asthma in an inner-city population had more favorable COVID-19 outcomes than patients who did not have asthma, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.“Few studies have examined COVID-19 infection specifically in inner-city patients with asthma,” Mydalyn D. Beronilla, MPH, clinical

Source: healio.com
Elevated HDL may improve SARS-CoV-2 infection resistance - Vimarsana News

Elevated HDL may improve SARS-CoV-2 infection resistance

LOUISVILLE, Ky. — Changes in HDL level may be linked with SARS-CoV-2 infection risk and subsequent outcomes in COVID-19, a speaker reported. Vignesh Chidambaram, MD MPH, internal medicine resident in the laboratory of Jawahar L. Mehta, MD, PhD, Stebbins Chair and professor of medicine at the college of medicine at the University of Arkansas for Medical Sciences, won the first-place

Source: healio.com
Top in hem/onc: Cell therapy approaches; low colorectal cancer screening rates - Vimarsana News

Top in hem/onc: Cell therapy approaches; low colorectal cancer screening rates

Strategies for cell therapy to treat cancer very depending on the type of tumor, according to experts.

Source: healio.com
Patients with history of autoimmune disease have fewer AAV relapses - Vimarsana News

Patients with history of autoimmune disease have fewer AAV relapses

Patients with ANCA-associated vasculitis who have a history of autoimmune disease prior to diagnosis may have fewer relapses following remission, according to data published in Clinical and Experimental Rheumatology.

Source: healio.com
Novel agent demonstrated tolerability, clinical response in patients with advanced NSCLC - Vimarsana News

Novel agent demonstrated tolerability, clinical response in patients with advanced NSCLC

For patients with advanced non-small cell lung cancer who showed an inadequate response to front-line immunotherapy checkpoint inhibitors and chemotherapy, the addition of CAN-2409 was well-tolerated. The preliminary clinical data of CAN-2409, a replication-deficient adenoviral gene construct that delivers the thymidine kinase gene, was presented at ASCO Annual Meeting.

Source: healio.com